Last reviewed · How we verify
NCT06761482: MONITOR
Non-Invasive Monitoring of Pediatric Kidney Transplant Recipients and Immunosuppression Personalization: an Open-labeled Multicenter Randomized Controlled Study
NA trial testing monitoring by dd-cfDNA in Pediatric Kidney Disease in 160 participants. Not yet recruiting.
1 March 2027
Quick facts
| Lead sponsor | Assistance Publique - Hôpitaux de Paris |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 160 |
| Start date | 1 March 2025 |
| Primary completion | 1 March 2027 |
| Estimated completion | 1 March 2029 |
| Sites | 1 location across France |
Drugs / interventions tested
- monitoring by dd-cfDNA
- monitoring by T-Vis
- monitoring by dd-cfDNA+ T-Vis
Conditions studied
- Pediatric Kidney Disease — all drugs for Pediatric Kidney Disease →
- Transplant;Failure,Kidney — all drugs for Transplant;Failure,Kidney →
Sponsor
Assistance Publique - Hôpitaux de Paris — full company profile →
Who can join
Adults 1 to 21, any sex, with Pediatric Kidney Disease or Transplant;Failure,Kidney. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Currently, the monitoring of children receiving a kidney transplantation includes surveillance biopsies to detect subclinical rejection and signs of toxicity of immunosuppressive drugs (tacrolimus). The hypothesis of the study is that the combination of non-invasive biomarkers (Donor-derived cell-free DNA and Virus-specific T cells) will allow both the safe discontinuation of surveillance biopsies and the personalization of the exposure to calcineurin inhibitors among pediatric kidney transplant recipients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06761482
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pediatric Kidney Disease
Currently open trials in the same condition.
- NCT06430684 — Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease · EARLY_PHASE1 · recruiting
- NCT05653492 — Safety, Feasibility, and Tolerability of Sulforaphane in Children with Chronic Kidney Disease · Phase 2 · active not recruiting
- NCT03719339 — VIRTUUS Children's Study · active not recruiting
Other Assistance Publique - Hôpitaux de Paris trials
Trials by the same sponsor.
- NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
- NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
- NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
- NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
- NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06761482 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
- Last refreshed: 7 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06761482.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing